Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 369
 
About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Advertise Login 
     


 
 Table of Contents  
EBN SYNOPSIS - EVIDENCE-BASED NEONATOLOGY SYNOPSIS
Year : 2012  |  Volume : 1  |  Issue : 2  |  Page : 64-66

Survival without disability to Age 5 years after neonatal caffeine therapy for Apnea of Prematurity


Consultant Neonatologist, King Faisal Specialist Hospital and Research Center, Saudi Arabia

Date of Web Publication29-May-2012

Correspondence Address:
Fahad Al Hazzani
Consultant Neonatologist, King Faisal Specialist Hospital and Research Center
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2249-4847.96742

Rights and Permissions

How to cite this article:
Al Hazzani F. Survival without disability to Age 5 years after neonatal caffeine therapy for Apnea of Prematurity. J Clin Neonatol 2012;1:64-6

How to cite this URL:
Al Hazzani F. Survival without disability to Age 5 years after neonatal caffeine therapy for Apnea of Prematurity. J Clin Neonatol [serial online] 2012 [cited 2022 Aug 9];1:64-6. Available from: https://www.jcnonweb.com/text.asp?2012/1/2/64/96742


  Context Top


Caffeine is the respiratory stimulant of choice for the treatment of apnea of prematurity. The international, randomized, placebo-controlled Caffeine for Apnea of Prematurity trial has shown that caffeine therapy reduces the duration of exposure to positive airway pressure and supplemental oxygen and the rates of neonatal morbidities, including bronchopulmonary dysplasia and severe retinopathy of prematurity; improves the rate of survival without neurodevelopmental impairment at 18-21 months of age. [1]


  Materials and Methods Top


Multicenter randomized controlled trial in 35 centers in Canada, United States, Australia, Europe and Israel. This follow-up study included long-term data from 31 centers only.

Population

Inclusion

  • Infants with a birth weight of 500-1250 g
  • Clinicians considered them to be candidates for methylxanthine therapy during the first 10 days of life.
Exclusion

  • Dysmorphic features or congenital anomalies likely to affect life expectancy or neurological development
  • Patient were unlikely to be available for long-term follow-up
  • Previously treated with methylxanthine
Intervention

Caffeine group

  • Caffeine citrate intravenous loading dose of 20 mg per kg of body weight. This was followed by a daily maintenance dose of 5 mg per kg
  • If apneas persisted, the daily maintenance dose could be increased to a maximum of 10 mg of caffeine citrate per kg per day
  • The maintenance doses were adjusted weekly for changes in body weight and could be given orally once an infant tolerated full enteral feedings.
Control

Equivalent volume of normal saline.

Outcomes

Primary

Original study

The primary outcome at a corrected age of 18-22 months is a composite of: Death, cerebral palsy, cognitive delay, deafness or blindness.

Current study

The primary outcome at a corrected age of 5 years is a composite of:

  • Death
  • Motor impairment (Gross Motor Function Classification System level of 3-5)
  • Cognitive impairment (defined as a Full Scale IQ<70)
  • Behavior problems defined as a Total Problem T score of greater than 69 (Child Behavior Checklist)
  • Poor general health defined as 1 or more of the following: need for supplemental oxygen, positive airway pressure, feeding through a tube or intravenously, seizures occurring more frequently than once per month, or a recent admission to ICU for complications resulting from a neonatal morbidity
  • Severe hearing loss was defined as the prescription of hearing aids or cochlear implants
  • Bilateral blindness was defined as a corrected visual acuity less than 20/200 in the better eye.
Other outcomes

Motor performance (Movement Assessment Battery for Children), Visual-Motor Integration, height, weight, and head circumference.

Allocation

  • A computer-generated randomization scheme was used to assign infants to the two groups in a 1:1 ratio
  • Randomization was stratified by study center and balanced in random blocks of two or four patients.
Blinding

Blinded, families, clinical, pharmacy and research staffs were unaware of group assignment.

Follow-up

Adequate data for the main outcome was available for 84.9 % of the children.


  Results Top


Five-year follow-up from 31 of 35 centers; 1932 of 2006 participants (96.3%) had been enrolled in the CAP trial between 1999 and 2004. A total of 1640 children (84.9%) had adequate data for the main outcome at 5 years.

The results for the primary composite outcome and for its components are shown in [Table 1]. The rates of motor impairment, severe cognitive impairment, behavior problems, poor general health, blindness, and deafness were not significantly different between the two groups.
Table 1: Primary outcome of death or disability

Click here to view


Only two children in each of the two groups died between 18 months and 5 years. A secondary analysis using the full ordinal scale of the GMFCS showed evidence of an improvement in gross motor function associated with caffeine therapy.

Change in motor and cognitive function between 18 months and 5 Years

Rates of moderate and severe cognitive impairments were much lower at 5 years than at 18 months. Only 33 of the 178 children (18.5%) with a Bayley II Mental Development Index less than 70 at 18 months had a Wechsler Preschool and Primary Scale of Intelligence III Full Scale IQ less than 70 at 5 years. On average, a child with a Mental Development Index of 70 at 18 months had a Wechsler Preschool and Primary Scale of Intelligence III Full Scale IQ that was almost 20 points higher at 5 years.


  Commentary Top


In the initial trial the use of caffeine significantly improved the outcome at a corrected age of 18-22 months in terms of composite outcome (death before 18 months and cerebral palsy, cognitive delay, severe hearing loss or bilateral blindness).

In the current study, neurobehavioral, neuropsychological, and motor outcomes were comprehensively evaluated at 5 years of age. In contrast to their earlier results, when the children were 5 years of age, CAP investigators found no effect of caffeine on the primary outcome of death or survival with severe disability, which was defined differently than the main trial as motor or cognitive impairment, behavior problems, poor general health, deafness, or blindness.

In contrast, a secondary analysis of the full range of motor outcomes suggests that the improved motor function observed at 18-21 months of age in the caffeine group was indeed sustained at 5 years.

The rates of cognitive impairment were much lower at 5 years than at 18 months and similar in the caffeine and placebo groups, which suggest that cognitive delay during the second year of life may not be a lasting outcome after very preterm birth. This study and other studies demonstrate that outcomes up to 2 years after very preterm birth may not accurately predict function later in childhood and how long-term follow-up is essential for reaching accurate conclusions about the efficacy of new therapies in preterm infants. [2],[3]

Abstracted from

Schmidt B, Anderson P, Doyle L, Dewey D, Grunau RE, Asztalos EV, et al. Survival Without Disability to Age 5 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. JAMA 2012;307:275-82.

 
  References Top

1.Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112-21.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2.Marlow N, Wolke D, Bracewell MA, Samara M. EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005;352:9-19.  Back to cited text no. 2
    
3.Roberts G, Anderson PJ, Doyle LW. Victorian Infant Collaborative Study Group. The stability of the diagnosis of developmental disability between ages 2 and 8 in a geographic cohort of very preterm children born in 1997. Arch Dis Child 2010; 95:786-90.  Back to cited text no. 3
    



 
 
    Tables

  [Table 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Context
Materials and Me...
Results
Commentary
References
Article Tables

 Article Access Statistics
    Viewed3097    
    Printed166    
    Emailed1    
    PDF Downloaded546    
    Comments [Add]    

Recommend this journal